CHMP recommends EU approval of Roche ’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer

Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news